Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs Oatly Group AB - ADR (OTLY) Price & Performance

AbbVie IncTrade
Oatly Group AB - ADRTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs Oatly Group AB - ADR — how do they compare? AbbVie Inc trades at $250 (market cap $438.19B), while Oatly Group AB - ADR trades at $12.93 (market cap $421.56M). The key difference: AbbVie Inc is far larger — about 1039.4× Oatly Group AB - ADR's market cap, and AbbVie Inc pays a 2.79% dividend while Oatly Group AB - ADR pays none. Which is the better fit depends on your goals.

ABBVOTLY
Market Cap
$438.19B$421.56M
Sector
HealthConsumer Staples
52-Week High
$263.58$18.54
52-Week Low
$197.38$8.03
Enterprise Value
$502.45B$925.97M
Dividend Yield
2.79%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

Oatly Group AB - ADR

Oatly (OTLY) trades at $13.72, up 0.22% with a bullish technical signal driven by moving averages and oversold RSI levels. Revenue growth improved to $862.46M in 2025, though net losses persist at -$152.77M. Recent Q2 2026 results beat EPS expectations, prompting a raised full-year revenue outlook to $925M, fueling a 29% stock surge on July 22, 2026 (GlobeNewsWire). The company shows progress toward adjusted EBITDA positivity, but cash burn remains a concern.

The outlook hinges on execution of margin expansion and cash flow improvement. Risks include high debt-to-asset ratio (66.53% in 2025) and intense competition. Analyst consensus is mixed with 44% buy ratings, but institutional sentiment is cautious due to profitability challenges. Upside potential exists if Oatly achieves sustained EBITDA positivity and reduces cash burn.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About Oatly Group AB - ADR

Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.

Read more on OTLY